LeaderPortfolio
Baumbach
Maximilian von Baumbach
Rank #610
GERMANYHealthcarePharma

Maximilian von Baumbach

Net Worth
$6.589B
0% (24h)
Maximilian von Baumbach, a 28-year-old German citizen, is an heir to the Boehringer Ingelheim fortune, making him a prominent figure in the pharmaceutical industry. His net worth is estimated at $6.6 billion, placing him among the world's wealthiest individuals. The source of his wealth is rooted in the pharmaceutical giant Boehringer Ingelheim, a company known for its significant contributions to healthcare. While specifics of his career trajectory remain private, his position as an heir indicates a deep involvement in the family business and its strategic direction. He is part of the fourth generation of the Boehringer and von Baumbach families to manage the company. Boehringer Ingelheim, founded in 1885, is the largest privately-owned pharmaceutical company in the world.

The Full Dossier

Early Life

Maximilian von Baumbach, born in Germany, is part of the von Baumbach family, known for their significant stake in the pharmaceutical company Boehringer Ingelheim. The company was founded in 1885, with roots going back to 1817.

Rise to Success

Maximilian's wealth stems from his inheritance within the Boehringer Ingelheim enterprise. The company has grown to become the largest privately-owned pharmaceutical company globally, with a presence in 130 markets and employing 53,000 people. He is part of the fourth generation of the Boehringer and von Baumbach families to manage the company.

Key Business Strategies

Boehringer Ingelheim focuses on long-term, sustainable action as an independent family-owned business, achieving this goal through sound financing and organic corporate growth. The company’s corporate culture is based on values established since its founding in 1885. The company's most well-known drugs treat COPD, anti-coagulation, and type 2 diabetes.

Philanthropy

While the exact details of Maximilian von Baumbach's philanthropic activities are not readily available, his association with a major pharmaceutical company suggests potential involvement in various health-related initiatives, in line with the company's values.

Career Timeline

2016

Hubertus von Baumbach becomes chairman

Hubertus von Baumbach, an heir, became chairman of Boehringer Ingelheim.

2001

Joined Boehringer Ingelheim

Joined the family business.

Philanthropic Impact

HealthcareUndisclosed

Boehringer Ingelheim Initiatives

Boehringer Ingelheim supports various initiatives related to healthcare and global health.

Wealth Trajectory